9 February 2009

Contents

Antiretrovirals

• Maraviroc safety label changes included with US traditional approval

• US approval of paediatric abacavir

• EMEA supports extension of D:A:D study until at least 2012 and the new remit to include non-AIDS cancers and kidney disease

• Applications to approve non-refrigerated ritonavir submitted to EMEA and FDA

PK and drug interactions

• Elvitegravir with tipranavir/ritonavir or darunavir/ritonavir

• Serum bilirubin increases when PEG-interferon and ribavirin are used with atazanavir

• Drug interactions with integrase inhibitors

• Drug interactions between efavirenz and itraconazole

• Effect on tacrolimus when switching from nelfinavir to fosamprenavir